Bevacizumab in Combination With Radiotherapy and Temozolomide for Patients With Newly Diagnosed Glioblastoma Multiforme

BACKGROUND. Patients with a newly diagnosed glioblastoma multiforme (GBM) have a high risk of recurrent disease with a dismal outcome despite intensive treatment of sequential surgery and chemoradiotherapy with temozolomide (TMZ), followed by TMZ as a single agent. Bevacizumab (BV) may increase resp...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: van Linde, Myra E., Verhoeff, Joost J.C., Richel, Dirk J., van Furth, Wouter R., Reijneveld, Jaap C., Verheul, Henk M.W., Stalpers, Lukas J.A.
Format: Artigo
Idioma:Inglês
Publicat: AlphaMed Press 2015
Matèries:
Clinical Trial Results
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4319643/
https://ncbi.nlm.nih.gov/pubmed/25582142
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0418
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars